이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Hansoh Pharmaceutical Group 미래 성장
Future 기준 확인 1/6
Hansoh Pharmaceutical Group (는) 각각 연간 2.4% 및 6.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 2.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.5% 로 예상됩니다.
주요 정보
2.4%
수익 성장률
2.0%
EPS 성장률
| Pharmaceuticals 수익 성장 | 9.2% |
| 매출 성장률 | 6.6% |
| 향후 자기자본 수익률 | 12.4% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 23 Sep 2024 |
최근 미래 성장 업데이트
Recent updates
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price
Nov 07Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Oct 11수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 13,912 | 4,468 | 4,384 | 4,242 | 20 |
| 12/31/2025 | 12,414 | 3,902 | 3,808 | 3,932 | 23 |
| 12/31/2024 | 12,064 | 4,150 | 3,668 | 3,364 | 23 |
| 6/30/2024 | 12,098 | 4,714 | 4,137 | 4,653 | N/A |
| 3/31/2024 | 11,101 | 3,996 | 3,446 | 3,885 | N/A |
| 12/31/2023 | 10,104 | 3,278 | 2,754 | 3,116 | N/A |
| 9/30/2023 | 9,782 | 2,926 | 2,292 | 2,615 | N/A |
| 6/30/2023 | 9,459 | 2,575 | 1,830 | 2,114 | N/A |
| 3/31/2023 | 9,421 | 2,579 | 2,140 | 2,427 | N/A |
| 12/31/2022 | 9,382 | 2,584 | 2,449 | 2,741 | N/A |
| 9/30/2022 | 9,675 | 2,652 | 2,646 | 3,004 | N/A |
| 6/30/2022 | 9,968 | 2,720 | 2,842 | 3,267 | N/A |
| 3/31/2022 | 9,952 | 2,717 | 2,472 | 2,922 | N/A |
| 12/31/2021 | 9,935 | 2,713 | 2,102 | 2,577 | N/A |
| 9/30/2021 | 9,524 | 2,675 | 1,415 | 2,345 | N/A |
| 6/30/2021 | 9,112 | 2,638 | 729 | 2,113 | N/A |
| 3/31/2021 | 8,901 | 2,603 | 840 | 2,252 | N/A |
| 12/31/2020 | 8,690 | 2,569 | 951 | 2,390 | N/A |
| 9/30/2020 | 8,377 | 2,526 | 1,775 | 2,802 | N/A |
| 6/30/2020 | 8,063 | 2,483 | 2,600 | 3,213 | N/A |
| 3/31/2020 | 8,373 | 2,520 | 2,666 | 3,271 | N/A |
| 12/31/2019 | 8,683 | 2,557 | 2,732 | 3,330 | N/A |
| 9/30/2019 | 8,615 | 2,357 | 2,529 | 3,092 | N/A |
| 6/30/2019 | 8,548 | 2,157 | 2,325 | 2,854 | N/A |
| 3/31/2019 | 8,135 | 2,030 | 2,008 | 2,463 | N/A |
| 12/31/2018 | 7,722 | 1,903 | 1,690 | 2,072 | N/A |
| 12/31/2017 | 6,186 | 1,595 | N/A | 1,402 | N/A |
| 12/31/2016 | 5,433 | 1,476 | N/A | 1,247 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 3692 의 연간 예상 수익 증가율( 2.4% )이 saving rate( 2.3% 보다 높습니다. ).
수익 vs 시장: 3692 의 연간 수익( 2.4% ) Hong Kong 시장( 11.7% 보다 느리게 성장할 것으로 예상됩니다. 11.7% 연간).
고성장 수익: 3692 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: 3692 의 수익(연간 6.9% ) Hong Kong 시장( 7.3% 보다 느리게 성장할 것으로 예상됩니다. 7.3% 연간).
고성장 수익: 3692 의 수익(연간 9.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 3692 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 12.6 %).